Compare MATW & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATW | ANL |
|---|---|---|
| Founded | 1850 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.3M | 731.6M |
| IPO Year | 1995 | 2022 |
| Metric | MATW | ANL |
|---|---|---|
| Price | $26.63 | $12.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 237.4K | 151.7K |
| Earning Date | 04-30-2026 | 04-10-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 59.07 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,795,737,000.00 | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.76 | $0.88 |
| 52 Week High | $30.93 | $17.25 |
| Indicator | MATW | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 46.16 |
| Support Level | $26.48 | $6.92 |
| Resistance Level | $27.87 | $12.09 |
| Average True Range (ATR) | 0.81 | 1.34 |
| MACD | -0.11 | -0.20 |
| Stochastic Oscillator | 40.40 | 25.57 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.